A Cost-Effectiveness Analysis of an Adenocarcinoma Risk Prediction Multi-Biomarker Assay for Patients With Barrett’s Esophagus

ClinicoEconomics and Outcomes Research - New Zealand
doi 10.2147/ceor.s221741
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Esophageal Adenocarcinoma in a First-Degree Relative Increases Risk for Esophageal Adenocarcinoma in Patients With Barrett’s Esophagus

United European Gastroenterology Journal
OncologyGastroenterology
2018English

Cost–effectiveness Analysis of Endoscopic Eradication Therapy for Treatment of High-Grade Dysplasia in Barrett’s Esophagus

Journal of Comparative Effectiveness Research
Health Policy
2017English

Review of Genomics of Barrett’s Esophagus and Esophageal Adenocarcinoma

Integrative Molecular Medicine
2015English

Progression of Barrett’s Esophagus to Adenocarcinoma Despite Antireflux Surgery

Endoscopy
Gastroenterology
2008English

Risk of Progression in Barrett’s Esophagus Indefinite for Dysplasia: A Systematic Review and Meta-Analysis

Gastrointestinal Endoscopy
Nuclear MedicineRadiologyImagingGastroenterology
2020English

Determining Risk of Barrett’s Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants

Gastroenterology
HepatologyGastroenterology
2018English

Genetic and Epigenetic Alterations in Barrett’s Esophagus and Esophageal Adenocarcinoma

Gastroenterology Clinics of North America
Gastroenterology
2015English

The Prevalence of Viral Agents in Esophageal Adenocarcinoma and Barrett’s Esophagus

European Journal of Gastroenterology and Hepatology
HepatologyGastroenterology
2017English

Endoscopic Eradication Therapy for Patients With Barrett’s Esophagus–associated Dysplasia and Intramucosal Cancer

Gastrointestinal Endoscopy
Nuclear MedicineRadiologyImagingGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy